AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17454036 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release (CR) tablets of naproxen sodium
Number of subjects: 6
Study 17454036 — intervention group
Group type: COMPARATOR
Intervention: Marketed immediate release tablets of naproxen sodium
Number of subjects: 6
Study 15154604 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day)
Number of subjects: 20
Study 15154604 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg/day)
Number of subjects: 20
Study 15154604 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus Aspirin
Number of subjects: 20
Study 11739070 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 11739070 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 11739070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9431857 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy (one or a combination of two first-line antihypertensive drugs) for 6 months
Number of subjects: 54
Study 9431857 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 54
Study 8099804 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 12
Study 8099804 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 mg vitamin C)
Number of subjects: 12
Study 3687354 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed information for at least 20 min
Number of subjects: 81
Study 3687354 — intervention group
Group type: COMPARATOR
Intervention: Routine information for about 5 min
Number of subjects: 81
Study 30361237 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (PROB) 1000 mg orally
Number of subjects: 14
Study 30361237 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (PROB) 1000 mg orally with Furosemide (FSM) 40 mg orally
Number of subjects: 14
Study 30361237 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (FSM) 40 mg orally
Number of subjects: 14
Study 28814399 — intervention group
Group type: COMPARATOR
Intervention: 0 g soybean oil
Number of subjects: 12
Study 28814399 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g soybean oil
Number of subjects: 12
Study 28814399 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g soybean oil
Number of subjects: 12
Study 28814399 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g soybean oil
Number of subjects: 12
Study 28814399 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 g soybean oil
Number of subjects: 12
Study 26507916 — intervention group
Group type: EXPERIMENTAL
Intervention: Panda (smartphone version of FPS-R)
Number of subjects: 128
Study 26507916 — intervention group
Group type: EXPERIMENTAL
Intervention: Panda (smartphone version of CAS)
Number of subjects: 128
Study 26507916 — intervention group
Group type: COMPARATOR
Intervention: Original FPS-R
Number of subjects: 128
Study 26507916 — intervention group
Group type: COMPARATOR
Intervention: Original CAS
Number of subjects: 128
Study 26507916 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for assessment tool
Number of subjects: 128
Study 23899930 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality indicators for medications (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β-blockers, aldosterone antagonists, hydralazine/nitrates, statin therapy, and warfarin)
Number of subjects: 32
Study 23899930 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality indicators for use (or planned use) of implantable intracardiac devices
Number of subjects: 32
Study 23899930 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality indicators for blood pressure control (<140/90 mm Hg)
Number of subjects: 32
Study 23899930 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional variations in quality indicators
Number of subjects: 32
Study 23899930 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal variation of quality indicators
Number of subjects: 32
Study 20647942 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration squatting (WBVS)
Number of subjects: 14
Study 20647942 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 14
Study 19423515 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplicor at 0.2 cutoff
Number of subjects: 3277
Study 19423515 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplicor at 1.5 cutoff
Number of subjects: 3277
Study 19423515 — intervention group
Group type: COMPARATOR
Intervention: hc2
Number of subjects: 3277
Study 19423515 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplicor
Number of subjects: 3277
Study 16753014 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg vitamin D3 supplementation
Number of subjects: 212
Study 16753014 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg vitamin D3 supplementation
Number of subjects: 212
Study 16753014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 16753014 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 212
Study 15546233 — intervention group
Group type: EXPERIMENTAL
Intervention: Repressor group
Number of subjects: 91
Study 15546233 — intervention group
Group type: EXPERIMENTAL
Intervention: High-anxious group
Number of subjects: 91
Study 15546233 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 91
Study 11744466 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg OD
Number of subjects: 536
Study 11744466 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 15 mg OD
Number of subjects: 536
Study 11744466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study 8626364 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (100-600 mg/day)
Number of subjects: 160
Study 8626364 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 160
Study 8626364 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 160
Study 8626364 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 160
Study 8626364 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone and Sertraline
Number of subjects: 160
Study 1420736 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol
Number of subjects: 18
Study 1420736 — intervention group
Group type: COMPARATOR
Intervention: ranitidine
Number of subjects: 18
Study 1420736 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 6607151 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 0
Study 31288630 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 20
Study 31288630 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 20
Study 31288630 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose
Number of subjects: 20
Study 31288630 — intervention group
Group type: EXPERIMENTAL
Intervention: Allulose
Number of subjects: 20
Study 31563804 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message intervention providing personalized normative feedback
Number of subjects: 183
Study 31563804 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 183
Study 29878382 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 2 weeks
Number of subjects: 2888
Study 29878382 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 4 weeks
Number of subjects: 2888
Study 29878382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2888
Study 27931214 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer support intervention (tailored face-to-face support, 2-3 hours per week)
Number of subjects: 196
Study 27931214 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 196
Study 24948798 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged training at threshold
Number of subjects: 0
Study 24948798 — intervention group
Group type: EXPERIMENTAL
Intervention: Double training paradigm
Number of subjects: 0
Study 22508366 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged fasting with food-related visual and odorous stimuli
Number of subjects: 12
Study 22508366 — intervention group
Group type: COMPARATOR
Intervention: Prolonged fasting without food-related visual and odorous stimuli
Number of subjects: 12
Study 20634300 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (methylprednisolone pulse for 3 days in months 1, 3, and 5, oral prednisone 0.5 mg/kg every other day, azathioprine 1.5 mg/kg per day for 6 months)
Number of subjects: 207
Study 20634300 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids alone (same schedule as group 1)
Number of subjects: 207
Study 20634300 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (with azathioprine)
Number of subjects: 207
Study 20634300 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids alone
Number of subjects: 207
Study 18085335 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (2001-2005)
Number of subjects: 42
Study 15580441 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 47
Study 15580441 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy
Number of subjects: 47
Study 11876694 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam enema (2 g mesalazine per day, Claversal Foam)
Number of subjects: 0
Study 11876694 — intervention group
Group type: COMPARATOR
Intervention: Liquid enema (4 g mesalazine per day, Salofalk enema)
Number of subjects: 0
Study 10030248 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive chemotherapy (neoadjuvant cisplatin 100 mg/m2 D1 and 5-fluorouracil 1 gm/m2 D1-D3, followed by four courses of the same after radiotherapy)
Number of subjects: 618
Study 10030248 — intervention group
Group type: COMPARATOR
Intervention: Radical radiotherapy alone (60-62.5 Gy nasopharyngeal dose)
Number of subjects: 618
Study 7741286 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (2.5 micrograms/kg)
Number of subjects: 40
Study 7741286 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.07 mg/kg)
Number of subjects: 40
Study 1416418 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP infusion at 10.0 pmol/kg/min
Number of subjects: 8
Study 1416418 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP infusion at 1.25 pmol/kg/min
Number of subjects: 8
Study 1416418 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP infusion at 3.0 pmol/kg/min
Number of subjects: 8
Study 1416418 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 8
Study 3933317 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal nitroglycerin (GTN) 3 mg administered 3 times daily
Number of subjects: 16
Study 3933317 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate (ISDN) 30 mg administered 4 times daily
Number of subjects: 16
Study 3933317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30117077 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention including classroom-based education sessions, take home assignments, and parenting workshops.
Number of subjects: 0
Study 30117077 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention
Number of subjects: 0
Study 28940681 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health education for caregivers and provision of ultrasonic cleaning devices
Number of subjects: 269
Study 28940681 — intervention group
Group type: COMPARATOR
Intervention: Control group with continued normal care
Number of subjects: 269
Study 25293676 — intervention group
Group type: EXPERIMENTAL
Intervention: New professional league players
Number of subjects: 408
Study 25293676 — intervention group
Group type: COMPARATOR
Intervention: Amateur level players (control)
Number of subjects: 408
Study 23278124 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (Legalon®) with desferrioxamine
Number of subjects: 97
Study 23278124 — intervention group
Group type: COMPARATOR
Intervention: Placebo with desferrioxamine
Number of subjects: 97
Study 22338362 — intervention group
Group type: EXPERIMENTAL
Intervention: Acustimulation
Number of subjects: 25
Study 22338362 — intervention group
Group type: COMPARATOR
Intervention: Acupressure
Number of subjects: 25
Study 22338362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 19477351 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 15 mg/day
Number of subjects: 1425
Study 19477351 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg/day
Number of subjects: 1425
Study 19477351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1425
Study 16902840 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT with wheeze detection (MCT("Wheeze"))
Number of subjects: 80
Study 16902840 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT with FEV1 decline (MCT("FEV1"))
Number of subjects: 80
Study 16902840 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT with either FEV1 decline or wheeze detection (MCT("FEV1Wheeze"))
Number of subjects: 80
Study 15126742 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% aqueous NCT solution (1 mL)
Number of subjects: 50
Study 15126742 — intervention group
Group type: COMPARATOR
Intervention: Otosporin (1 mL)
Number of subjects: 50
Study 11405326 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper fourth of the BMD distribution
Number of subjects: 282
Study 11405326 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper fourth of the BMD distribution after adjusting for serum hormone levels
Number of subjects: 282
Study 11405326 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper fourth of the BMD distribution after adjusting for body mass index and years since menopause
Number of subjects: 282
Study 9322475 — intervention group
Group type: COMPARATOR
Intervention: CO2 pneumoperitoneum (IAP 12‐13 mm Hg) (control)
Number of subjects: 30
Study 9322475 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasless abdominal wall lift method (retractor)
Number of subjects: 30
Study 8461682 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 12
Study 3963318 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral flunitrazepam
Number of subjects: 600
Study 3963318 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pentobarbital
Number of subjects: 600
Study 3963318 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral NaCl solution
Number of subjects: 600
Study 3963318 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pethidine
Number of subjects: 600
Study 3963318 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular droperidol/fentanyl
Number of subjects: 600
Study 3963318 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular NaCl solution
Number of subjects: 600
Study 29511819 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCs (n=9)
Number of subjects: 18
Study 29511819 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCs+PRP (n=9)
Number of subjects: 18
Study 29511819 — intervention group
Group type: COMPARATOR
Intervention: MSCs and MSCs+PRP
Number of subjects: 18
Study 25914349 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 intravesical BoNT‐A injections (100 U in 10 mL)
Number of subjects: 67
Study 25914349 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 intravesical BoNT‐A injections (100 U in 10 mL)
Number of subjects: 67
Study 25914349 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 intravesical BoNT‐A injections (100 U in 10 mL)
Number of subjects: 67
Study 25914349 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (10, 20, 40 injections)
Number of subjects: 67
Study 25385363 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 99
Study 25385363 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 99
Study 25385363 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs)
Number of subjects: 99
Study 25385363 — intervention group
Group type: COMPARATOR
Intervention: Control (cerebral post-stroke injury without seizures)
Number of subjects: 99
Study 22085338 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage bevacizumab (15 mg/kg)
Number of subjects: 2210
Study 22085338 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dosage bevacizumab (7.5 mg/kg)
Number of subjects: 2210
Study 22085338 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (both dosages)
Number of subjects: 2210
Study 22085338 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 2210
Study 20370912 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Number of subjects: 2269
Study 20370912 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Number of subjects: 2269
Study 20370912 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol 300 mg (200 mg in moderate renal impairment)
Number of subjects: 2269
Study 18371100 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar-anchored overdentures
Number of subjects: 328
Study 18371100 — intervention group
Group type: COMPARATOR
Intervention: Telescopic crown-retained overdentures
Number of subjects: 328
Study 15855014 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16 L1 VLP vaccine
Number of subjects: 24
Study 15855014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12441935 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone plus prednisone
Number of subjects: 120
Study 12441935 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 120
Study 10616257 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual administration of HGSHS:A, TAS, DES, PCI
Number of subjects: 80
Study 10616257 — intervention group
Group type: COMPARATOR
Intervention: Group administration of HGSHS:A, TAS, DES, PCI
Number of subjects: 80
Study 7575761 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation of cyclosporine
Number of subjects: 10
Study 7575761 — intervention group
Group type: COMPARATOR
Intervention: Control preparation of cyclosporine
Number of subjects: 10
Study 7575761 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specific method for measuring pharmacokinetic parameters
Number of subjects: 10
Study 2040241 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glucose
Number of subjects: 70
Study 2040241 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 70
Study 2040241 — intervention group
Group type: COMPARATOR
Intervention: No intravenous fluids
Number of subjects: 70
Study 7431199 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent subjects (Fl-I and FD-I)
Number of subjects: 80
Study 7431199 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects (Fl-I, FD-I, Fl-E, FD-E)
Number of subjects: 80
Study 31765520 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard electrode position
Number of subjects: 30
Study 31765520 — intervention group
Group type: COMPARATOR
Intervention: Alternative electrode positions (lateral, superior, medial, inferior, dorsal)
Number of subjects: 30
Study 31765520 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial and inferior electrode placement
Number of subjects: 30
Study 31765520 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral electrode placement
Number of subjects: 30
Study 31870417 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 70
Study 31870417 — intervention group
Group type: COMPARATOR
Intervention: Spinal Anesthesia (SA)
Number of subjects: 70
Study 31870417 — intervention group
Group type: COMPARATOR
Intervention: Spinal Anesthesia (SA) with sedation
Number of subjects: 70
Study 27882470 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar TURBT
Number of subjects: 160
Study 27882470 — intervention group
Group type: COMPARATOR
Intervention: Monopolar TURBT
Number of subjects: 160
Study 25528104 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (AT) group
Number of subjects: 24
Study 25528104 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture stimulation (AS) group
Number of subjects: 24
Study 23371492 — intervention group
Group type: COMPARATOR
Intervention: 20 mg cortisol
Number of subjects: 67
Study 23371492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 21447750 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex group (received messages related to safer sex)
Number of subjects: 7606
Study 21447750 — intervention group
Group type: COMPARATOR
Intervention: Sun group (received messages related to sun safety)
Number of subjects: 7606
Study 21447750 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex group
Number of subjects: 7606
Study 19735771 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) combined with a defined therapy program
Number of subjects: 21
Study 19735771 — intervention group
Group type: COMPARATOR
Intervention: Therapy alone
Number of subjects: 21
Study 19735771 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) combined with therapy
Number of subjects: 21
Study 19735771 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BTX‐A and therapy alone)
Number of subjects: 21
Study 18067007 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg) with thalidomide/dexamethasone
Number of subjects: 72
Study 18067007 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin with thalidomide/dexamethasone
Number of subjects: 72
Study 18067007 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin with lenalidomide-containing regimen (clarithromycin, lenalidomide, dexamethasone)
Number of subjects: 72
Study 18067007 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone alone (without aspirin)
Number of subjects: 72
Study 15519009 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin with provisional GP IIb/IIIa inhibition
Number of subjects: 4651
Study 15519009 — intervention group
Group type: COMPARATOR
Intervention: Heparin + routine GP IIb/IIIa inhibition
Number of subjects: 4651
Study 11304812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL)
Number of subjects: 25
Study 11304812 — intervention group
Group type: COMPARATOR
Intervention: Contact lens (CL)
Number of subjects: 25